Overview

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Status:
Completed

Trial end date:
2019-01-11

Target enrollment:

Participant gender:

Summary

The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for seizure.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborators:

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Medivation, Inc.